Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Pascal Biosciences Inc. (V:PAS)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for PAS within the last 6 months
See all filings within the past 6 months

Company News

Jun 16, 2021 05:30 ET
Hardy Forzley Joins Pascal Biosciences as Chief Financial Officer
VANCOUVER, BC / ACCESSWIRE / June 16, 2021 / Pascal Biosciences Inc. ("Pascal") (TSXV:PAS) (OTC PINK:PSCBF) (FSE:6PB), announced today the appointment of Hardy Forzley as Chief Financial Officer. Mr. Forzley has used his professional expertise as a Certified Public Accountant with some 30 years of experience in the field to raise capital, optimize corporate structure, and provide valuable operational oversight for numerous diverse companies.
Read full article
Jun 08, 2021 05:30 ET
Pascal Biosciences Awarded NIH Grant For Leukemia Program
VANCOUVER, BC / ACCESSWIRE / June 8, 2021 / Pascal Biosciences Inc. ("Pascal" or the "Company") (TSXV:PAS)(OTC PINK:PSCBF), has been awarded a grant of US$343,750 from the National Cancer Institute of the US National Institutes of Health (NIH). This two-year award will fund development of Pascal's antibody drug for Acute Lymphoblastic Leukemia (ALL), which is the most common childhood leukemia.
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jul 15, 20211,0640
May 31, 2021768400
May 15, 2021368-25,632
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Pascal Biosciences Inc, formerly Biommune Technologies Inc, is a Canada-based biopharmaceutical company. The Company is a research and development issuer. The Company is engaged in the research and development of products for the treatment of cancers, and for improvement of the immune system. The Company operates in the segment of biotechnology research and development. The Company focuses on cancer, infectious and autoimmune diseases. It offers various technologies, such as Major Histocompatibility Complex I (MHC I), a molecule that transports normal, abnormal and foreign protein fragments (peptides) to the surface of the cells, where the fragments are then exposed to the immune system's T Cells; CD74, a chaperone protein that is involved in the presentation of MHC I and MHC II molecules on cell surfaces, and Calcium Channel Blockers, which are methods and agents that modulate voltage-gated calcium channels.

See business summary



Search (past week) for $PAS.CA PAS.V

  • No tweets found